Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

|<

<

1

2

3

4

5

6

7

8

9

10

11

12

13

14

>

>|

Found 144 Matches

Dihydroartemisinin (DHA) from Artesunate
Model Files Publication

Brand Name(s) include: Camoquin (FDC with amodiaquine)

Disease: Malaria

Drug Class: Antimalarials

Related Drugs: DHA, Amodiaquine

Date Updated: March 2022

The model at-a-glance

  Absorption Model
  • First-Order

  Volume of Distribution

  • Full PBPK (Method 2)

Note: Kp scalar used

  Route of Elimination
  • UGT1A9 (50%); UGT2B7(50%)

  Perpetrator DDI
  • CYP1A2 Inhibitor

  Validation

  • One clinical study describing single dose exposure of DHA was used to verify the PBPK model.  100% of studies were within 2-fold, of which 100% were within 1.5-fold. 

  Limitations
  • The absorption model does not consider the formation of ‘DHA from artesunate’ mechanistically. Instead, an optimized ka and fa were applied to the DHA model to describe the observed plasma concentration-time curve of DHA. The remainder of the DHA model was identical to the DHA model which is described above.
  • The model does not account for the differences in plasma fraction unbound observed in patients compared to healthy volunteers.
  • Verification needed for perpetrator DDI assessment as literature data is unavailable at this time.

  Updates in V19
  • Updated in vitro data
    • Propranolol Papp: 30 cm/s x 106
  • Converted model to full PBPK with Vss predicted through Method 2
  • Updated retrograde clearance

 

Search Score: 11
Famotidine_V15R1_USFDA_20170810
Model Files Publication
http://onlinelibrary.wiley.com/doi/10.1002/cpt.750/full Famotidine compound file in healthy volunteers. Evaluation of the effect of renal impairment on the PK of OAT substrates. NOTE: MW is slightly different between model file and Table 1.
Search Score: 11
FostamatinibMetR406_V19R1_Pfizer_20210804
Model Files Publication
An optimized Rosuvastatin (V19) model was used and DDIs predominantly driven by gut BCRP inhibition are reasonably recovered. Altogether, the following inhibitors were used: Capmatinib Fenebrutinib Fostamatinib Itraconazole Zepatier The workspace represents the DDI between Rosuvastatin and Fostamatinib metabolite R406. Link to the publication with further details: http://doi.org/10.1002/psp4.12672
Search Score: 11
TB Compound File Collection
Model Files Publication
V16 TB compound files and associated manuscript, as well as South African TB population file.
Search Score: 11

|<

<

1

2

3

4

5

6

7

8

9

10

11

12

13

14

>

>|